The following adverse effects were reported in patients receiving semaglutide injection or oral tablets across all clinical trials and at incidences higher than with placebo: nausea (11% to 44%), vomiting (5% to 24%), diarrhea (8.5% to 30%), abdominal pain (5.7% to 20%), abdominal distention (2% to 7%), constipation (3.1% to 24%), dyspepsia (0.6% to 9%), decreased appetite (6% to 9%), eructation (0.6% to 7%), flatulence (0.4% to 6%), gastroesophageal reflux disease (1.5% to 5%), gastroenteritis (4% to 6%), and gastritis (0.4% to 4%)
Source: pubchem Sequence: GEPPPGKPADDAGLV Molecular Formula: CHNO Molecular Weight: ~1419.54 Da PubChem CID: 9941957 BPC-157 may be used in laboratory studies involving: All uses are limited to research settings only
Originally developed by Metabolic Pharmaceuticals in Australia, it was designed as a shorter, modified version of hGH to retain its fat-burning (lipolytic) properties
When you're ready to conduct serious research, we're ready to be your trusted partner
those with more tissue can insert closer to perpendicular